Usefulness of the BTA stat Test for the diagnosis of bladder cancer

Baños, J.L. Gutiérrez; Rodrigo, María del Henar Rebollo; Juárez, Francisco Manuel Antolín; García, B. Martín

doi:10.1016/s0090-4295(00)01090-6

Cited by 42 publications

(21 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results are available in 5 min. All the tests have a control window to prevent misreadings or errors [9] . The sensitivity of this test varies from 57 to 78% and the specifi city from 52 to 93% ( table 2 ).…”

Section: Bta Statmentioning

confidence: 99%

Non-Invasive Diagnostic Tests for Bladder Cancer: A Review of the Literature

Bassi

Marco

Lisa³

et al. 2005

Urol Int

View full text Add to dashboard Cite

Transitional cell carcinoma of the bladder is the second most common malignancy of the genitourinary tract. Cystoscopy and urine cytology are the traditional most used techniques for diagnosis and surveillance of superficial bladder cancer. Urine cytology is specific for diagnosis of bladder cancer but sensitivity results not high, particularly in low-grade disease. Voided urine can be easily obtained and therefore additional diagnostic urine tests would be ideal for screening or follow-up of transitional cell carcinoma. A number of studies have focused on the evaluation of urinary markers that hold promise as non-invasive adjuncts to conventional diagnostic or surveillance techniques. In this review we discuss several new urinary markers (test for bladder tumor antigen, NMP22^®, fibrin degradation products, telomerase, fluorescence in situ hybridization test, flow cytometry) and their role in detection and follow-up of bladder cancer. Most of these markers have higher sensitivity than urine cytology, but voided urine cytology has the highest specificity.

show abstract

Section: Bta Statmentioning

confidence: 99%

Non-Invasive Diagnostic Tests for Bladder Cancer: A Review of the Literature

Bassi

Marco

Lisa³

et al. 2005

Urol Int

View full text Add to dashboard Cite

show abstract

“…Using high throughput genomics and proteomics technologies, we performed molecular analyses of voided urine with the goal of identifying novel urinary biomarkers that can improve the accuracy of detecting BCa over that of current urine based assays, eg urinary cytology, 2 bladder tumor antigen, 3 nuclear matrix protein 22 4 and others. 5 We derived genomic 6 and proteomic signatures 7,8 that achieved highly accurate detection of BCa in noninvasively obtained urine samples.…”

mentioning

confidence: 99%

Diagnostic Potential of Urinary α1-Antitrypsin and Apolipoprotein E in the Detection of Bladder Cancer

Urquidi¹,

Goodison²,

Ross³

et al. 2012

Journal of Urology

View full text Add to dashboard Cite

Purpose The ability to reliably diagnose bladder cancer in voided urine samples would be a major advance. Using high throughput technologies, we identified a panel of bladder cancer associated biomarkers with potential clinical usefulness. In this study we tested 4 potential biomarkers for the noninvasive detection of bladder cancer. Materials and Methods We examined voided urine specimens from 124 patients, including 63 newly diagnosed with bladder cancer and 61 controls. Concentrations of proteins were assessed by enzyme-linked immunosorbent assay, including α1-antitrypsin, apolipoprotein E, osteopontin and pentraxin 3. Data were compared to the results of urinary cytology and the BTA Trak® enzyme-linked immunosorbent assay based bladder cancer detection assay. We used the AUC of ROC curves to compare the usefulness of each biomarker to detect bladder cancer. Results Urinary levels of α1-antitrypsin, apolipoprotein E and bladder tumor antigen were significantly increased in subjects with bladder cancer. α1-Antitrypsin (AUC 0.9087, 95% CI 0.8555–0.9619) and apolipoprotein E (AUC 0.8987, 95% CI 0.8449–0.9525) were the most accurate biomarkers. The combination of α1-antitrypsin and apolipoprotein E (AUC 0.9399) achieved 91% sensitivity, 89% specificity, and a positive and negative predictive value of 89% and 90%, respectively. Multivariate regression analysis highlighted only apolipoprotein E as an independent predictor of bladder cancer (OR 24.9, 95% CI 4.22–146.7, p = 0.0004). Conclusions Alone or in combination, α1-antitrypsin and apolipoprotein E show promise for the noninvasive detection of bladder cancer (OR 24.9, 95% CI 4.22– 146.7, p = 0.0004). Larger, prospective studies including more low grade, low stage tumors are needed to confirm these results.

show abstract

“…Human complement factor H-related protein [51,52] BladderChek Measure protein in urine, quantitatively via ELISA or qualitatively via immunochromatography (BladderChek). Nuclear matrix protein-22 [53,54] ImmunoCyt/uCyt+…”

Section: Magnetic Resonance Imaging (Mri)mentioning

confidence: 99%

“…As an alternate direction to cell-free DNA as a biomarker for detection of bladder cancer, many assays and devices intended to screen cases of bladder cancer rely on the binding of antibodies to protein species present in patient urine [51][52][53][54]73,95,96]. Particularly common is plate-based ELISA, in which antibodies are coated onto wells of a plate and incubated with clinical liquid samples.…”

Section: Antibody-bonded Substratesmentioning

confidence: 99%

Microdevices for Non-Invasive Detection of Bladder Cancer

et al. 2017

View full text Add to dashboard Cite

Bladder cancer holds the record for the highest lifetime cost on a per-patient basis. This is due to high recurrence rates, which necessitate invasive and costly long-term evaluation methods such as cystoscopy and imaging. Microfluidics is emerging as an important approach to contribute to initial diagnosis and follow-up, by enabling the precise manipulation of biological samples. Specifically, microdevices have been used for the isolation of cells or genetic material from blood samples, sparking significant interest as a versatile platform for non-invasive bladder cancer detection with voided urine. In this review, we revisit the methods of bladder cancer detection and describe various types of markers currently used for evaluation. We detail cutting-edge technologies and evaluate their merits in the detection, screening, and diagnosis of bladder cancer. Advantages of microscale devices over standard methods of detection, as well as their limitations, are provided. We conclude with a discussion of criteria for guiding microdevice development that could deepen our understanding of prognoses at the level of individual patients and the underlying biology of bladder cancer development. Collectively, the development and widespread application of improved microfluidic devices for bladder cancer could drive treatment breakthroughs and establish widespread, tangible outcomes on patients' long-term survival.

show abstract

Usefulness of the BTA stat Test for the diagnosis of bladder cancer

Cited by 42 publications

References 14 publications

Non-Invasive Diagnostic Tests for Bladder Cancer: A Review of the Literature

Non-Invasive Diagnostic Tests for Bladder Cancer: A Review of the Literature

Diagnostic Potential of Urinary α1-Antitrypsin and Apolipoprotein E in the Detection of Bladder Cancer

Microdevices for Non-Invasive Detection of Bladder Cancer

Contact Info

Product

Resources

About